Abstract. The aim of the present study was to investigate the expression of B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) in vulvar squamous cell carcinoma (VSCC) and vulvar intraepithelial neoplasia (VIN). Furthermore, the present study investigated the effects of BMI-1 expression on the biological behavior of A-431 human epidermoid carcinoma cells. BMI-1 expression in human VSCC and VIN tissues was detected using immunohistochemistry. Subsequently, BMI-1 expression was silenced in A-431 cells using small interfering RNA (siRNA), and BMI-1 expression was detected using reverse transcription-quantitative polymerase chain reaction and western blotting. The effects of BMI-1 silencing on cell proliferation, apoptosis and invasive ability were determined using an MTT assay, Annexin V-fluorescein isothiocyanate/propidium iodide double-labeling experiment and Transwell assay, respectively. The expression rate of BMI-1 in normal vulvar, VIN and VSCC tissues was 0.0, 25.0 and 68.0% respectively, demonstrating an increasing trend in the severity of the disease. BMI-1 overexpression was found not to correlate with age, pathological stage, lymph node metastasis or degree of differentiation (P>0.05). BMI-1 siRNA transfection effectively inhibited BMI-1 messenger RNA and protein expression in A-431 cells. The mean rate of apoptosis promotion and proliferation inhibition in the most effectively silenced group were 20.19 and 46.82%, respectively, which was significantly higher than that of the cells in the blank and control siRNA groups (P<0.05). The number of invading cells was decreased in the most effectively silenced group compared with that of the blank and control siRNA groups. Abnormal expression of BMI-1 was also detected in VIN and VSCC tissues, and targeting of BMI-1 with siRNA was able to successfully silence BMI-1 expression in A-431 cells. Silencing of BMI-1 promoted apoptosis and inhibited the invasive abilities of A-431 cells in vitro.
Introduction
Vulvar cancer is the fourth most common gynecological cancer worldwide, comprising 5% of total malignancies observed in the female reproductive tract (1) . Squamous cell carcinoma is the most commonly observed pathological type of vulvar cancer (2) . Vulvar carcinoma is most frequently diagnosed in postmenopausal females and the mean age at diagnosis has been revealed to be 65 years, although this number has been observed to be decreasing (3) . In recent years, vulvar squamous cell carcinoma (VSCC) incidence has increased (4) . Vulvar intraepithelial neoplasia (VIN) is the precursor lesion of VSCC and its incidence is also increasing, according to data from the Surveillance, Epidemiology, and End Results Program (4) . Young patients with VIN generally heal spontaneously without treatment, howvever, patients >60 years old or young patients with immunosuppression may develop invasive cancer.
B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) is a stem cell factor and member of the polycomb group (PCG) family (5) . BMI-1 is important for cell cycle progression, cell immortalization and senescence, and has been reported to regulate the proliferative activities of normal, stem and progenitor cells (6) . Numerous studies have demonstrated that BMI-1 expression, which is upregulated in multiple types of cancer, is positively correlated with clinical grade/stage and poor prognosis in cervical (7), ovarian (8) , endometrial (9) and lung (10) cancer. Silencing of BMI-1 expression by RNA interference (RNAi) has been observed to decrease the rate of tumor cell growth, resulting in cell cycle arrest and inhibition of the invasive ability of tumor cells (11) (12) (13) (14) . In the present study, BMI-1 expression in VSCC was examined, and the effect of small-interfering RNA (siRNA)-mediated silencing of BMI-1 in A-431 cells was investigated.
Materials and methods
Tissue samples. All experiments were approved by the Ethics Committee of China Medical University (Liaoning, China). A total of 125 paraffin-embedded tissue specimens, including 75 VSCC, 40 vulvar intraepithelial neoplasia (VIN) and 10 normal vulvar samples adjacent to the carcinoma, were subjected to immunohistochemical analysis. The samples used in the present study were obtained from the Department RT-qPCR assay. Following 24 h of transfection, total RNA was extracted from A-431 cells using TRIzol reagent (Invitrogen Life Technologies) The primers used were as follows: BMI-1 sense, 5'-TGGACTGACAAATGCTGGAGA-3' and antisense, 5'-GAAGATTGGTGGTTACCGCTG-3'; β-actin sense, 5'-CATTAAGGAGAAGCTGTGCT-3' and antisense, 5'-GTTGAAGGTAGTTTCGTGGA-3' (Shanghai GenePharma Co., Ltd.). RT-qPCR reactions were performed using the SYBR Green method with the AccuPower Greenstar qPCR Master mix (Bioneer Corp., Daejeon, Korea) on a Rotor-Gene 6000 (Corbett Research Pty Ltd., Sydney, Australia). Table I . Expression of BMI-1 in various types of vulvar tissue. Table II . Correlations between BMI-1 expression and clinicopathological parameters. at 16,000 x g for 10 min at 4˚C, supernatants were collected and the protein concentration was measured using bicinchoninic acid assay reagent (BioTeke Corp., Beijing, China). Proteins were separated by 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Immobilon-Ny+; both from Beyotime Institute of Biotechnology). Following saturation, the membranes were incubated at room temperature for 2 h in Tris-buffered saline with 0.1% Tween-20 (Beyotime Institute of Biotechnology) containing 5% non-fat dry milk (Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China). The membranes were subsequently incubated with primary antibodies against BMI-1 (1:400 dilution) overnight at 4˚C and subjected to secondary detection using HRP-conjugated immunoglobulin G (H+L) antibodies [goat anti-rabbit polyclonal; cat no. LK-GAR007; 1:4,000 dilution; Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou, China] at room temperature for 2 h. Protein detection was performed using an LumiPico® enhanced chemiluminescence kit (Nanjing Keygen Biotech. Co. Ltd., Nanjing, China). GAPDH antibody (mouse anti-human monocloanl; cat no. sc-365062; 1:800 dilution; Santa Cruz Biotechnology, Inc.) was used as a protein loading control.
MTT assay. In order to measure cell growth, cells transfected for 24 h were seeded into 96-well plates at a density of 1x10 5 /ml in a volume of 100 µl, and allowed to grow for 6-8 h. Cells were then divided into three groups as follows: A blank group, transfected with an identical volume of opti-MEM medium/Lipofectamine 2000; a negative control group, transfected with Apoptosis assay. Apoptosis was assayed using the Annexin V-fluorescein isothiocyanate (FITC) apoptosis kit (Beyotime Institute of Biotechnology). Briefly, cells transfected for 24 h were harvested and washed twice with PBS, followed by resuspension in 10 µl Annexin V binding buffer. Subsequently, FITC-conjugated Annexin V and propidium iodide were added. Following incubation for 15 min at room temperature in the dark, an additional binding buffer was added and cells were incubated for 5 min at 6-8˚C. Samples were analyzed immediately by flow cytometry (Cell Lab Quanta™ SC; Beckman Coulter, Inc.). Cells were divided into three groups as follows: Normal A-431 cells (without transfection), negative control group (transfected with negative control siRNA) and best transfection group (transfected with the most effective siRNA).
Transwell chamber invasion assay. The polycarbonate membranes (8 µm-pores) of Transwell inserts were coated with Matrigel (BD Biosciences, San Jose, CA, USA). Cells were resuspended in serum-free minimum essential medium (MEM; Gibco Life Technologies) and seeded into the upper wells in the three groups described previously. MEM medium supplemented with 15% fetal bovine serum was placed into the lower chamber. Following incubation for 24 h at 37˚C, the inserts were removed and cells which had migrated through the membranes and attached to the lower chamber were photographed using an Olympus BX60 microscope and counted.
Statistical analysis.
All experiments were performed a minimum of three times and the results were analyzed using 
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SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Values were expressed as the mean ± standard deviation. The analysis of variance test was used when >2 groups were compared and P<0.05 was considered to indicate a statistically significant difference.
Results

Differential expression of BMI-1 in VSCC, VIN and normal vulvar tissues.
Immunohistochemical staining demonstrated that the expression rate of BMI-1 in VIN tissues differed significantly from that in normal vulvar tissues (25 vs. 0%; P<0.05). In addition, the positive expression rate of BMI-1 in VSCC tissues significantly differed from that in VIN and normal vulvar tissues (68.0 vs. 25.0% and 0%; both P<0.0001; Fig. 1 ; Table I ). BMI-1 protein overexpression was not observed to be correlated with age, pathological stage, lymph node metastasis or degree of differentiation (P>0.05; Table II) .
Effects of BMI-1 on the biological behavior of A-431 cells
Transfection efficiency of BMI-1. siRNA-mediated BMI-1 silencing was used to examine the effect of the BMI-1 protein on the biological behavior of A-431 cells. The highest transfection efficiency was observed at 24 h. Cells were counted under a fluorescence microscope, which revealed that the transfection efficiency was >80% at 24 h (data not shown). Tables III and IV and Fig. 3 and 4 reveal that, compared with 
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the blank and control siRNA groups, the experimental BMI-1 siRNAs effectively inhibited BMI-1 expression at the mRNA and protein levels in A-431 cells. This was particularly evident in the siRNA-2 group (siRNA-1 group vs. siRNA-2 group, P<0.0001; siRNA-3 group vs. siRNA-2 group, P<0.0001; t-test method). Therefore, siRNA-2 was selected for use in all subsequent experiments. BMI-1 silencing reduces proliferation and invasion, and enhances apoptosis in A-431 cells. MTT and Annexin V-FITC assays were used to evaluate the proliferation and apoptosis of A-431 cells. The results of the present study revealed that 24 h following transfection, the cell survival rate of the siRNA-2 group was 53.17±1.53%, which was significantly reduced compared with that of the blank (98.77±0.98%) and control siRNA groups (98.79±1.74%; Table V ). The apoptotic rate of the siRNA-2 group was 20.19±0.04%, which was significantly increased compared with the apoptotic rates of the blank (5.75±0.08%) and control siRNA groups (5.63±0.11%; Fig. 5 ; Table VI ). In invasion experiments, the number of penetrating cells in the siRNA-2 group was 21.67±2.42, which was significantly reduced compared with the number of penetrating cells in the blank (33.17±2.92) and control siRNA groups (33.50±3.02) ( Fig. 6 ; Table VII ).
Discussion
The occurrence and development of VSCC is a multi-step process involving numerous factors. The BMI-1 gene is involved in cell proliferation and apoptosis as an oncogene (5) . The results of the present study demonstrate that BMI-1 is overexpressed in VSCC and VIN, which is consistent with the results of previous studies of BMI-1 overexpression in cervical (7), nasopharyngeal (8) and lung cancer (10) . A previous study revealed that BMI-1 is expressed in the nucleus, since high BMI-1 expression levels is able to inhibit Ink4a/Arf expression by increasing H2AubiK119 and H3metK27 histone levels via the PCG pathway (15) . However, in the present study, BMI-1 was detected mainly in the cytoplasm, suggesting that the target of BMI-1 in VSCC may not be Ink4a/Arf. Further research may be required to elucidate the underlying mechanisms.
The correlation between the BMI-1 expression in tumors, and clinicopathological data, has been investigated in several previous studies. Tong et al (7) demonstrated that overexpression of BMI-1 in cervical cancer was correlated with tumor progression, lymph node metastasis, vascular invasion and HPV infection, suggesting that subtypes of cervical cancer which overexpress BMI-1 may possess a high metastatic potential. Choi et al (16) observed that patients with breast cancer associated with BMI-1 overexpression possessed favorable overall survival rates, particularly amongst patients with estrogen receptor-positive breast cancer. However, in hepatocellular carcinoma, Wang et al (17) reported that overexpression of BMI-1 was not associated with clinicopathological parameters. The results of the aforementioned studies suggest that BMI-1 possesses varying roles in different types of cancer. The results of the present study demonstrated that the overexpression of BMI-1 in VSCC was not correlated with age, pathological stage, lymph node metastasis or degree of differentiation, which was in accordance with the findings of Wang et al (17) and suggests that BMI-1 may be a candidate biomarker for VSCC.
To investigate the effect of BMI-1 on VSCC cell growth and malignant phenotypes, the RNAi method was used in the present study to silence BMI-1 expression in A-431 cells. It was demonstrated that the silencing of BMI-1 may significantly inhibit A-431 cell proliferation through the promotion of apoptosis. Numerous studies have revealed that BMI-1 has a role in tumor development, invasion and metastasis (11) (12) (13) (14) 18) . Destruction of the extracellular matrix and migration into the vascular system are key steps required for tumor metastasis (19) . In the present study, it was demonstrated that silencing of BMI-1 expression efficiently decreased the number of invading cells, indicating that BMI-1 may be important in the determination of the invasive ability of VSCC cells.
In conclusion, BMI-1 expression is altered in VIN and VSCC and this may be significant for proliferation, apoptosis and invasion. siRNA targeting of BMI-1 successfully silenced BMI-1 expression in A-431 cells, and silencing BMI-1 significantly promoted apoptosis and inhibited the invasive and metastatic abilities of A-431 cells in vitro. The results of the present study suggest that BMI-1 may be a candidate biomarker for VSCC and may provide an experimental target for VSCC gene therapy.
